-+ 0.00%
-+ 0.00%
-+ 0.00%
IDEXX Laboratories Exec Says ~1/4th Of Cancerdx Orders In Q3 Came From Non-Primary Reference Lab Customers; Covet Rev Run Rate Is About $20M Annualized, Growing At Strong Double-Digit Rates
Share
Listen to the news

https://event.webcasts.com/starthere.jsp?ei=1778007&tp_key=2e8c83027b

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending